Synergistic effects of insulin resistance and revascularization completeness on prognosis in patients with coronary artery calcification

医学 内科学 心脏病学 血运重建 经皮冠状动脉介入治疗 危险系数 心肌梗塞 胰岛素抵抗 蒂米 冠状动脉疾病 血管病学 狭窄 置信区间 前瞻性队列研究 糖尿病 经皮 队列研究 队列 比例危险模型 外科 心力衰竭 风险因素 四分位间距 子群分析 弗雷明翰风险评分
作者
Zhangyu Lin,Yanjun Song,Sheng Yuan,Bowen Li,Jining He,Kefei Dou
出处
期刊:Cardiovascular Diabetology [BioMed Central]
卷期号:25 (1) 被引量:1
标识
DOI:10.1186/s12933-026-03196-y
摘要

BACKGROUND: The association between percutaneous coronary intervention (PCI) outcomes for moderate-to-severe coronary artery calcification (MSCAC) lesions and long-term clinical outcomes in individuals with varying levels of insulin resistance is not well-defined. This study aims to examine the relationship between MSCAC-PCI outcomes and long-term poor clinical outcomes in individuals with varying insulin resistance statuses. METHODS: This prospective cohort research comprised 4,087 patients who received MSCAC-PCI at Fuwai Hospital from January 2017 to December 2018. Patients were classified according to MSCAC-PCI outcomes: failure (device uncrossable or no change in lesion stenosis severity), suboptimal revascularization (meeting neither the criteria for optimal revascularization nor procedural failure), and optimal revascularization (post-PCI TIMI grade = 3 and residual stenosis < 30%). The insulin resistance status was assessed utilizing the triglyceride-glucose (TyG) index, and patients were classified based on baseline TyG tertiles (tertile 1 [T1]: <8.66; T2: 8.66–9.14; T3: ≥9.14). The primary outcome was the composite of cardiovascular (CV) death and target-vessel myocardial infarction (TVMI). RESULTS: During the median follow-up period of 3 years, 154 (3.77%) patients with primary outcomes were recorded. There were 267 instances of MSCAC-PCI failure, 274 instances of suboptimal revascularization, and 3546 instances of optimal revascularization. Patients who underwent optimal revascularization exhibited markedly reduced risks of CV death/TVMI (adjusted hazard ratio [aHR], 0.53; 95% confidence interval [CI], 0.32–0.87) in comparison to those experiencing MSCAC-PCI failure. No significant difference was observed between patients who got suboptimal revascularization and those with MSCAC-PCI failure. Subgroup analysis indicated that patients in the TyG T3 subgroup have a diminished risk of CV death/TVMI (aHR, 0.45; 95% CI, 0.21–0.97) following optimal revascularization, mostly attributable to a decreased risk of CV death (aHR, 0.29; 95% CI, 0.10–0.78) after optimal revascularization. No substantial variations were observed in PCI outcomes between the TyG T1 and T2 subgroups of patients. CONCLUSIONS: Our findings suggest that optimal revascularization during PCI is associated with improved long-term clinical outcomes in patients with MSCAC, particularly in those with a high level of insulin resistance.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小仙女完成签到,获得积分20
刚刚
123dyj完成签到,获得积分20
刚刚
刘勇发布了新的文献求助10
1秒前
1秒前
2秒前
思源的应助被热情冰夏采纳,获得10
2秒前
3秒前
JamesPei的应助被飞翔的荷兰猪采纳,获得10
3秒前
lhw发布了新的文献求助10
4秒前
le完成签到,获得积分10
4秒前
5秒前
Ziyang_Lee完成签到,获得积分10
5秒前
王达达完成签到 ,获得积分10
5秒前
詩翰发布了新的文献求助10
5秒前
桐桐的应助被南宫硕采纳,获得10
7秒前
7秒前
周巍发布了新的文献求助10
7秒前
勤恳的画笔完成签到 ,获得积分10
8秒前
Leon完成签到,获得积分10
9秒前
THEO完成签到,获得积分10
9秒前
ljf123456完成签到,获得积分10
10秒前
10秒前
cyc111完成签到,获得积分10
10秒前
赘婿的应助被enjoy采纳,获得10
10秒前
10秒前
hahahaha完成签到 ,获得积分10
11秒前
地米关注了科研通微信公众号
11秒前
11秒前
呆呆叹气完成签到,获得积分10
12秒前
12秒前
13秒前
13秒前
13秒前
Piautos完成签到,获得积分20
14秒前
15秒前
fanmingdong发布了新的文献求助10
15秒前
AAAaa发布了新的文献求助10
16秒前
redtea完成签到,获得积分10
16秒前
17秒前
Jessy发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191965
求助须知:如何正确求助?哪些是违规求助? 9578608
关于积分的说明 21860774
捐赠科研通 7791420
什么是DOI,文献DOI怎么找? 3436743
关于科研通互助平台的介绍 2560487
邀请新用户注册赠送积分活动 2483544